Zymeworks rises after Ziihera shows significant PFS and OS benefits in a Phase 3 trial, supporting plans for regulatory filings and guideline submissions.
Sealed Air agrees to $10.3B all-cash acquisition by CD&R, offering $42.15 per share—a 41% premium. Company begins 30-day go-shop period for alternative bids.